{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084251","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.644417+00:00","generated_at":"2026-05-15T22:39:56.493454+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DBV Technologies reports additional positive Phase 3 VITESSE data for VIASKIN Peanut Patch at AAAAI 2026","bullets":["82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.","24% of placebo group decreased eliciting dose over 12 months vs 6.4% of treated group, indicating reduced sensitization.","VIASKIN Peanut Patch was well tolerated; most adverse events were mild local application site reactions.","Company plans to submit Biologics License Application (BLA) to FDA in the first half of 2026.","All sensitivity analyses significant; response rate difference exceeded prespecified 15% threshold."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084251","json":"https://secwatch.observer/filing/0001193125-26-084251.json","markdown":"https://secwatch.observer/filing/0001193125-26-084251.md","text":"https://secwatch.observer/filing/0001193125-26-084251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/0001193125-26-084251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/d110966d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:39:56.493454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}